Depression and Quality of Life in Psoriasis

References

• . Stern RS, Nijsten T, Feldman SR, Margolis DJ, Rolstad T. Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction. J Investig Dermatol Symp Proc. 2004;9(2):136–139
   PubMed Web of Science ®Google Scholar
• . Weiss SC, Kimball AB, Liewehr DJ, Blauvelt A, Turner ML, Emanuel EJ. Quantifying the harmful effect of psoriasis on health-related quality of life. J Am Acad Dermatol. 2002;47(4):512–518
   PubMed Web of Science ®Google Scholar
• . Devrimci-Ozguven H, Kundakci TN, Kumbasar H, Boyvat A. The depression, anxiety, life satisfaction and affective expression levels in psoriasis patients. J Eur Acad Dermatol Venereol. 2000;14(4): 267–271
   PubMed Web of Science ®Google Scholar
• . Gupta MA, Gupta AK. Depression and suicidal ideation in dermatology patients with acne, alopecia areata, atopic dermatitis and psoriasis. Br J Dermatol. 1998;139(5):846–850
   PubMed Web of Science ®Google Scholar
• . Esposito M, Saraceno R, Giunta A, Maccarone M, Chimenti S. An Italian study on psoriasis and depression. Dermatology. 2006;212(2): 123–127
   PubMed Web of Science ®Google Scholar
• . Sampogna F, Gisondi P, Melchi CF, Amerio P, Girolomoni G, Abeni D; IDI Multipurpose Psoriasis Research on Vital Experiences Investigators. Prevalence of symptoms experienced by patients with different clinical types of psoriasis. Br J Dermatol. 2004;151(3):594–599
   PubMed Web of Science ®Google Scholar
• . Choi J, Koo JY. Quality of life issues in psoriasis. J Am Acad Dermatol. 2003;49( 2 Suppl):S57–S61
   PubMed Web of Science ®Google Scholar
• . Gupta MA, Gupta AK, Watteel GN. Perceived deprivation of social touch in psoriasis is associated with greater psychologic morbidity: an index of the stigma experience in dermatologic disorders. Cutis. 1998;61(6):339–342
   PubMedGoogle Scholar
• . Schmid-Ott G, Jaeger B, Kuensebeck HW, Ott R, Lamprecht F. Dimensions of stigmatization in patients with psoriasis in a “Questionnaire on Experience with Skin Complaints”. Dermatology. 1996;193(4):304–310
   PubMedGoogle Scholar
• . Pearce DJ, Singh S, Balkrishnan R, Kulkarni A, Fleischer AB, Feldman SR. The negative impact of psoriasis on the workplace. J Dermatolog Treat. 2006;17(1):24–28
   PubMed Web of Science ®Google Scholar
• . Schmitt J, Meurer M, Klon M, Frick KD. Assessment of health state utilities of controlled and uncontrolled psoriasis and atopic eczema: a population-based study. Br J Dermatol. 2008;158(2):351–359
   PubMed Web of Science ®Google Scholar
• . Kimball AB, Jacobson C, Weiss S, Vreeland MG, Wu Y. The psychosocial burden of psoriasis. Am J Clin Dermatol. 2005;6(6): 383–392
   PubMed Web of Science ®Google Scholar
• . Richards HL, Fortune DG, Weidmann A, Sweeney SK, Griffiths CE. Detection of psychological distress in patients with psoriasis: low consensus between dermatologist and patient. Br J Dermatol. 2004;151(6):1227–1233
   PubMed Web of Science ®Google Scholar
• . Schmitt JM, Ford DE. Role of depression in quality of life for patients with psoriasis. Dermatology. 2007;215(1):17–27
   PubMed Web of Science ®Google Scholar
• . Altobelli E, Maccarone M, Petrocelli R, . Analysis of health care and actual needs of patients with psoriasis: a survey on the Italian population. BMC Public Health. 2007;7:59
   PubMedGoogle Scholar
• . Kirby B, Richards HL, Mason DL, Fortune, DG, Main CJ, Griffiths CE. Alcohol consumption and psychological distress in patients with psoriasis. Br J Dermatol. 2008;158(1):138–140
   PubMed Web of Science ®Google Scholar
• . Richards HL, Fortune DG, Griffiths CE, Main CJ. The contribution of perceptions of stigmatisation to disability in patients with psoriasis. J Psychosom Res. 2001;50(1):11–15
   PubMed Web of Science ®Google Scholar
• . Kiliç A, Güleç MY, Gül U, Güleç H. Temperament and character profile of patients with psoriasis. J Eur Acad Dermatol Venereol. 2008;22(5):537–542
   PubMed Web of Science ®Google Scholar
• . Conrad R, Geiser F, Haidl G, Hutmacher M, Liedtke R, Wermter F. Relationship between anger and pruritus perception in patients with chronic idiopathic urticaria and psoriasis. J Eur Acad Dermatol Venereol. 2008;22(9):1062–1069
   PubMedGoogle Scholar
• . Richards HL, Fortune DG, Chong SL, . Divergent beliefs about psoriasis are associated with increased psychological distress. J Invest Dermatol. 2004;123(1):49–56
   PubMed Web of Science ®Google Scholar
• . Kulkarni AS, Balkrishnan R, Camacho FT, Anderson RT, Feldman SR. Medication and health care service utilization related to depressive symptoms in older adults with psoriasis. J Drugs Dermatol. 2004;3(6):661–666
   PubMedGoogle Scholar
• . Krueger G, Koo J, Lebwohl M, Menter A, Stern RS, Rolstad T. The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol. 2001;137(3):280–284
   PubMed Web of Science ®Google Scholar
• . Rapp SR, Feldman SR, Exum ML, Fleischer AB Jr, Reboussin DM. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol. 1999;41(3 pt 1):401–407
   PubMed Web of Science ®Google Scholar
• . Sampogna F, Chren MM, Melchi CF, Pasquini P, Tabolli S, Abeni D; Italian Multipurpose Psoriasis Research on Vital Experiences (Improve) Study Group. Age, gender, quality of life and psychological distress in patients hospitalized with psoriasis. Br J Dermatol. 2006;154(2):325–331
   PubMed Web of Science ®Google Scholar
• . Schön MP, Boehncke WH. Psoriasis. N Engl J Med. 2005;352(18):1899–1912
   PubMed Web of Science ®Google Scholar
• . Gottlieb AB, Chao C, Dann F. Psoriasis comorbidities. J Dermatolog Treat. 2008;19(1):5–21
   PubMed Web of Science ®Google Scholar
• . Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB. Risk of myocardial infarction in patients with psoriasis. JAMA. 2006;296(14):1735–1741
   PubMed Web of Science ®Google Scholar
• . Gelfand JM, Shin DB, Neimann AL, Wang X, Margolis DJ, Troxel AB. The risk of lymphoma in patients with psoriasis. J Invest Dermatol. 2006;126(10):2194–2201
   PubMed Web of Science ®Google Scholar
• . Gladman DD. Psoriatic arthritis. Dermatol Ther. 2004;17(5):350–63
   PubMedGoogle Scholar
• . Libby P. Atherosclerosis: disease biology affecting the coronary vasculature. Am J Cardiol. 2006;98(12A):3Q–9Q
   PubMed Web of Science ®Google Scholar
• . Adler UC, Marques AH, Calil HM. Inflammatory aspects of depression. Inflamm Allergy Drug Targets. 2008;7(1):19–23
   PubMedGoogle Scholar
• . Illman J, Corringham R, Robinson D Jr, . Are inflammatory cytokines the common link between cancer-associated cachexia and depression? J Support Oncol. 2005;3(1):37–50
   PubMedGoogle Scholar
• . Simen BB, Duman CH, Simen AA, Duman RS. TNFalpha signaling in depression and anxiety: behavioral consequences of individual receptor targeting. Biol Psychiatry. 2006;59(9):775–785
   PubMedGoogle Scholar
• . Zachariae R, Zachariae H, Blomqvist K, . Self-reported stress reactivity and psoriasis-related stress of Nordic psoriasis sufferers. J Eur Acad Dermatol Venereol. 2004;18(1):27–36
   PubMedGoogle Scholar
• . Naldi L, Chatenoud L, Linder D, . Cigarette smoking, body mass index, and stressful life events as risk factors for psoriasis: results from an Italian case-control study. J Invest Dermatol. 2005;125(1):61–67
   PubMed Web of Science ®Google Scholar
• . O'Leary CJ, Creamer D, Higgins E, Weinman J. Perceived stress, stress attributions and psychological distress in psoriasis. J Psychosom Res. 2004;57(5):465–471
   PubMedGoogle Scholar
• . Picardi A, Mazzotti E, Gaetano P, . Stress, social support, emotional regulation, and exacerbation of diffuse plaque psoriasis. Psychosomatics. 2005;46(6):556–564
   PubMedGoogle Scholar
• . Picardi A, Pasquini P, Cattaruzza MS, . Only limited support for a role of psychosomatic factors in psoriasis. Results from a case-control study. J Psychosom Res. 2003;55(3):189–196
   PubMedGoogle Scholar
• . Bahmer JA, Kuhl J, Bahmer FA. How do personality systems interact in patients with psoriasis, atopic dermatitis and urticaria? Acta Derm Venereol. 2007;87(4):317–324
   PubMed Web of Science ®Google Scholar
• . Hardy GE, Cotterill JA. A study of depression and obsessionality in dysmorphophobic and psoriatic patients. Br J Psychiatry. 1982;140:19–22
   PubMed Web of Science ®Google Scholar
• . Gupta MA, Schork NJ, Gupta AK, Kirkby S, Ellis CN. Suicidal ideation in psoriasis. Int J Dermatol. 1993;32(3):188–190
   PubMed Web of Science ®Google Scholar
• . Fortune DG, Richards HL, Kirby B, McElhone K, Main CJ, Griffiths CE. Successful treatment of psoriasis improves psoriasis-specific but not more general aspects of patients' well-being. Br J Dermatol. 2004;151(6):1219–1226
   PubMedGoogle Scholar
• . Fortune DG, Richards HL, Kirby B, Bowcock S, Main CJ, Griffiths CE. A cognitive-behavioural symptom management programme as an adjunct in psoriasis therapy. Br J Dermatol. 2002;146(3):458–465
   PubMed Web of Science ®Google Scholar
• . Revicki DA, Willian MK, Menter A, Saurat JH, Harnam N, Kaul M. Relationship between clinical response to therapy and health-related quality of life outcomes in patients with moderate to severe plaque psoriasis. Dermatology. 2008;216(3):260–270
   PubMed Web of Science ®Google Scholar
• . Fortune DG, Richards HL, Kirby B, . Psychological distress impairs clearance of psoriasis in patients treated with photochemotherapy. Arch Dermatol. 2003;139(6):752–756
   PubMedGoogle Scholar
• . Soriatane [package insert]. Palo Alto, CA: Connetics; 2004
   Google Scholar
• . Gelfand JM, Kimball AB, Mostow EN, . Patient-reported outcomes and health-care resource utilization in patients with psoriasis treated with etanercept: continuous versus interrupted treatment. Value Health. 2008;11(3):400–107
   PubMed Web of Science ®Google Scholar
• . Tyring S, Gottlieb A, Papp K, . Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. Lancet. 2006;367(9504):29–35
   PubMed Web of Science ®Google Scholar
• . Tyring S, Gordon KB, Poulin Y, . Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis. Arch Dermatol. 2007;143(6):719–726
   PubMed Web of Science ®Google Scholar
• . Moore A, Gordon KB, Kang S, . A randomized, open-label trial of continuous versus interrupted etanercept therapy in the treatment of psoriasis. J Am Acad Dermatol. 2007;56(4):598–603
   PubMed Web of Science ®Google Scholar
• . Militello G, Xia A, Stevens SR, Van Voorhees AS. Etanercept for the treatment of psoriasis in the elderly. J Am Acad Dermatol. 2006;55(3):517–519
   PubMed Web of Science ®Google Scholar
• . Gordon K, Korman N, Frankel E, . Efficacy of etanercept in an integrated multistudy database of patients with psoriasis. J Am Acad Dermatol. 2006;54(3 Suppl 2):S101–S111
   PubMed Web of Science ®Google Scholar
• . De Felice C, Mazzotta A, Esposito M, Bianchi L, Chimenti S. High-dose initiation of etanercept in psoriatic arthritis and plaque psoriasis: efficacy, safety and impact on patients' quality of life. J Dermatolog Treat. 2006;17(6):355–358
   PubMed Web of Science ®Google Scholar
• . Cassano N, Loconsole F, Galluccio A, Miracapillo A, Pezza M, Vena GA. Once-weekly administration of high-dosage Etanercept in patients with plaque psoriasis: results of a pilot experience (power study). Int J Immunopathol Pharmacol. 2006;19(1):225–229
   PubMedGoogle Scholar
• . Krueger GG, Langley RG, Finlay AY, . Patient-reported outcomes of psoriasis improvement with etanercept therapy: results of a randomized phase III trial. Br J Dermatol. 2005;153(6):1192–1199
   PubMed Web of Science ®Google Scholar
• . Feldman SR, Kimball AB, Krueger GG, Woolley JM, Lalla D, Jahreis A. Etanercept improves the health-related quality of life of patients with psoriasis: results of a phase III randomized clinical trial. J Am Acad Dermatol. 2005;53(5):887–889
   PubMed Web of Science ®Google Scholar
• . Leonardi CL, Powers JL, Matheson RT, ; Etanercept Psoriasis Study Group. Etanercept as monotherapy in patients with psoriasis. N Engl J Med. 2003;349(21):2014–2022
   PubMed Web of Science ®Google Scholar
• . Gottlieb AB, Matheson RT, Lowe N, . A randomized trial of etanercept as monotherapy for psoriasis. Arch Dermatol. 2003;139(12):1627–1632; discussion 32
   PubMed Web of Science ®Google Scholar
• . Feldman SR, Gottlieb AB, Bala M, . Infliximab improves health-related quality of life in the presence of comorbidities among patients with moderate-to-severe psoriasis. Br J Dermatol. 2008;159(3):704–710
   PubMed Web of Science ®Google Scholar
• . Menter A, Feldman SR, Weinstein GD, . A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. J Am Acad Dermatol. 2007;56(1):31. e1-15
   PubMed Web of Science ®Google Scholar
• . Reich K, Nestle FO, Papp K, . Improvement in quality of life with infliximab induction and maintenance therapy in patients with moderate-to-severe psoriasis: a randomized controlled trial. Br J Dermatol. 2006;154(6):1161–1168
   PubMed Web of Science ®Google Scholar
• . Feldman SR, Gordon KB, Bala M, . Infliximab treatment results in significant improvement in the quality of life of patients with severe psoriasis: a double-blind placebo-controlled trial. Br J Dermatol. 2005;152(5):954–960
   PubMed Web of Science ®Google Scholar
• . Gottlieb AB, Evans R, Li S, . Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol. 2004;51(4):534–542
   PubMed Web of Science ®Google Scholar
• . Revicki D, Willian MK, Saurat JH, . Impact of adalimumab treatment on health-related quality of life and other patient-reported outcomes: results from a 16-week randomized controlled trial in patients with moderate to severe plaque psoriasis. Br J Dermatol. 2008;158(3):549–557
   PubMed Web of Science ®Google Scholar
• . Revicki DA, Willian MK, Menter A, . Impact of adalimumab treatment on patient-reported outcomes: results from a Phase III clinical trial in patients with moderate to severe plaque psoriasis. J Dermatolog Treat. 2007;18(6):341–350
   PubMed Web of Science ®Google Scholar
• . Shikiar R, Heffernan M, Langley RG, Willian MK, Okun MM, Revicki DA. Adalimumab treatment is associated with improvement in health-related quality of life in psoriasis: patient-reported outcomes from a phase II randomized controlled trial. J Dermatolog Treat. 2007;18(1):25–31
   PubMed Web of Science ®Google Scholar
• . Traczewski P, Rudnicka L. Adalimumab in dermatology. Br J Clin Pharmacol. 2008;66(5):618–625
   PubMedGoogle Scholar
• . Revicki DA, Menter A, Feldman S, Kimel M, Harnam N, Willian MK. Adalimumab improves health-related quality of life in patients with moderate to severe plaque psoriasis compared with the United States general population norms: results from a randomized, controlled Phase III study. Health Qual Life Outcomes. 2008;6:75
   PubMed Web of Science ®Google Scholar
• . Ellis CN, Mordin MM, Adler EY; Randomized, placebo-controlled phase II trial. Effects of alefacept on health-related quality of life in patients with psoriasis: results from a randomized, placebo-controlled phase II trial. Am J Clin Dermatol. 2003;4(2):131–139
   PubMedGoogle Scholar
• . Feldman SR, Menter A, Koo JY. Improved health-related quality of life following a randomized controlled trial of alefacept treatment in patients with chronic plaque psoriasis. Br J Dermatol. 2004;150(2): 317–326
   PubMedGoogle Scholar
• . Gordon KB, Papp KA, Hamilton TK, ; Efalizumab Study Group. Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial. JAMA. 2003;290(23):3073–3080
   PubMed Web of Science ®Google Scholar
• . Ortonne J P, Shear N, Shumack S, Henninger E; CLEAR Multinational Study Group. Impact of efalizumab on patient-reported outcomes in high-need psoriasis patients: results of the international, randomized, placebo-controlled Phase III Clinical Experience Acquired with Raptiva (CLEAR) trial [NCT00256139]. BMC Dermatol. 2005;5:13
   PubMedGoogle Scholar